Scottish Medicines Consortium recommends Zebinix but rejects others
This article was originally published in Scrip
Executive Summary
In its latest round of deliberations, Scotland's health technology assessment agency, the Scottish Medicines Consortium, recommended the epilepsy drug Zebinix (eslicarbazepine acetate), from Eisai, but rejected a whole raft of drugs including PharmaMar's Yondelis (trabectedin) for some patients with advanced soft tissue sarcoma.